Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Down syndrome and Alzheimer's

Topic: Risk, prevention and care in population studies

Plain-language summary

Methods TOP-COG was a feasibility/pilot, double-blind RCT of 12 months simvastatin 40 mg versus placebo for the primary prevention of dementia in Alzheimer disease in Down syndrome adults aged 50 years or older. Results were analysed on an intention-to-treat basis. Results We identified 181 (78 %) of the likely eligible Down syndrome population, and recruited 21 (11.6 %), from an area with a general population size of 3,135,974. Aβ40 levels changed less for the simvastatin group (not statistically significant).

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 21 participants. This pilot trial of simvastatin 40 mg versus placebo in adults with Down syndrome aged 50 or older recruited only 21 people and found that Aβ40 levels changed less for the simvastatin group, which was not statistically significant. As a small feasibility study, it does not show that simvastatin prevents dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cooper, S. A., Ademola, T., Caslake, M., Douglas, E., Evans, J., Greenlaw, N., et al. (2016). Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials. https://doi.org/10.1186/s13063-016-1370-9

Vancouver

Cooper SA, Ademola T, Caslake M, Douglas E, Evans J, Greenlaw N, et al. Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials. 2016. doi:10.1186/s13063-016-1370-9. PMID: 27473843.

BibTeX

@article{cooper2016-27473843,
  author  = {Cooper, S. A. and Ademola, T. and Caslake, M. and Douglas, E. and Evans, J. and Greenlaw, N. and Haig, C. and Hassiotis, A. and others},
  title   = {{Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial}},
  journal = {Trials},
  year    = {2016},
  doi     = {10.1186/s13063-016-1370-9},
  pmid    = {27473843},
  url     = {https://doi.org/10.1186/s13063-016-1370-9}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This pilot trial of simvastatin 40 mg versus placebo in adults with Down syndrome aged 50 or older recruited only 21 people and found that Aβ40 levels changed less for the simvastatin group, which was not statistically significant. As a small feasibility study, it does not show that simvastatin prevents dementia.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 60 of 100.60 of 100 points earned40 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Trials)
Journal's citation record 1 / 4 Trials: journal h-index 132 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2016 — within 20 year(s) of the newest study here
Sample size 1 / 4 21 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 27 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.2 citations a year over 12 year(s) since 2016
Impact for its field and year 2 / 6 Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Frank Sullivan: h-index 70 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 27473843)
Free to read 2 / 2 Free to read
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →